share_log
Moomoo 24/7 ·  03/28 11:30

Sutro Biopharma Shares Are Trading Higher After Oppenheimer Maintained Its Outperform Rating and $10 Price Target on the Stock. The Company Recently Reported 2023 Financial Results

在奥本海默维持其跑赢大盘的评级和10美元的目标股价之后,Sutro Biopharma的股价走高。该公司最近公布了2023年财务业绩

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发